Stay updated with breaking news from Expanded Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SHELTON, CT / ACCESSWIRE / August 4, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines
Jynneos is a live, nonreplicating, smallpox and monkeypox vaccine; ACAM2000 is a live smallpox (vaccinia) vaccine.
Tpoxx was FDA-approved in 2018 as the first drug to treat smallpox, a virus in the same family as monkeypox.
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022....
Q2 2022 total revenues were $64.4 millionTotal revenues in the first six months of 2022 were $124.6 millionVanda provides update on pipeline advan...